Franklin Resources Inc. Acquires 48,708 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Franklin Resources Inc. boosted its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 4.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,118,688 shares of the specialty pharmaceutical company's stock after acquiring an additional 48,708 shares during the quarter. Franklin Resources Inc. owned about 1.85% of Jazz Pharmaceuticals worth $124,208,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in JAZZ. CWA Asset Management Group LLC purchased a new position in Jazz Pharmaceuticals during the 3rd quarter valued at $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Jazz Pharmaceuticals by 135.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company's stock worth $19,394,000 after purchasing an additional 100,112 shares during the last quarter. Pacer Advisors Inc. increased its stake in Jazz Pharmaceuticals by 15.3% in the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company's stock worth $233,892,000 after buying an additional 278,465 shares during the period. Philip James Wealth Mangement LLC bought a new stake in Jazz Pharmaceuticals during the 3rd quarter valued at about $830,000. Finally, Thompson Siegel & Walmsley LLC boosted its position in Jazz Pharmaceuticals by 30.6% in the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 721,530 shares of the specialty pharmaceutical company's stock valued at $77,009,000 after buying an additional 168,957 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on JAZZ. Piper Sandler reiterated an "overweight" rating and set a $163.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday. HC Wainwright reissued a "buy" rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Robert W. Baird upped their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an "outperform" rating in a research report on Monday, November 18th. Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their target price for the company from $140.00 to $175.00 in a research report on Thursday. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. Two equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $177.00.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ traded up $2.16 during mid-day trading on Monday, reaching $125.20. 766,954 shares of the company traded hands, compared to its average volume of 668,194. The stock has a fifty day simple moving average of $117.39 and a 200-day simple moving average of $112.22. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The firm has a market cap of $7.57 billion, a PE ratio of 17.63, a price-to-earnings-growth ratio of 1.02 and a beta of 0.57. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $134.17.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the transaction, the chief executive officer now owns 428,976 shares of the company's stock, valued at $47,547,699.84. The trade was a 0.23 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Neena M. Patil sold 3,700 shares of the firm's stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the transaction, the executive vice president now directly owns 33,048 shares in the company, valued at $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,753 shares of company stock worth $816,289 in the last three months. 4.20% of the stock is currently owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.